Trial Profile

Effects of GLP-1 Analogues on Fluid Intake in Patients With Primary Polydipsia: "The GOLD-Study"

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 16 Feb 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Dulaglutide (Primary)
Indications Polydypsia
Focus Therapeutic Use
Acronyms GOLD

Most Recent Events

03 Feb 2022 Results investigating the effect of a three-week treatment with the GLP-1 RA dulaglutide on vasoactive hormones using 2 randomized crossover trials published in the Journal of Clinical Endocrinology and Metabolism
23 Mar 2021 Primary endpoint (Fluid intake in ml) has been met, as per results presented at the 103rd Annual Meeting of the Endocrine Society.
23 Mar 2021 Results assessing efficacy of GLP-1 receptor agonists to reduce fluid intake in patients with primary polydipsia, presented at the 103rd Annual Meeting of the Endocrine Society.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com